ENPP1 Agent Composition for DISH Calcification and Bone Overgrowth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diffuse idiopathic skeletal hyperostosis (DISH), Ankylosing Spondylitis, and Spondylarthritis are inadequate, with a lack of understanding regarding the role of ENPP1, TNAP, and ANK in these conditions, and no effective therapies to prevent or reverse pathological calcification and bone overgrowth.
Innovation Solution
Administration of an ENPP1 agent, comprising the catalytic region of ENPP1 with optional human IgG Fc domain or human serum albumin, to increase extracellular pyrophosphate concentrations and target bones, thereby treating and preventing DISH, Ankylosing Spondylitis, and Spondylarthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for DISH, Ankylosing Spondylitis, and Spondylarthritis are used, then symptomatic relief may be achieved, but pathological calcification and bone overgrowth cannot be prevented or reversed
Solution Approach 1:
The patent converts the harmful effect of uncontrolled calcification into a beneficial therapeutic approach by using pyrophosphate (a natural inhibitor of calcification) at controlled concentrations to prevent and reverse pathological calcification in DISH, Ankylosing Spondylitis, and Spondylarthritis, thereby addressing the root cause rather than just symptoms
Solution Approach 2:
The patent changes the concentration parameter of pyrophosphate in the extracellular environment to achieve therapeutic effects. By administering compositions that elevate pyrophosphate levels to specific therapeutic ranges, the patent prevents hydroxyapatite deposition and reverses existing calcification, transforming a biochemical parameter to treat the disease
2Stability of the object's composition
If ENPP1, TNAP, and ANK enzyme activities are not regulated, then physiological balance is maintained, but pathological calcification occurs
Solution Approach 1:
The patent implements a feedback mechanism by monitoring and regulating pyrophosphate levels in the extracellular environment. By administering compositions containing pyrophosphate or agents that modulate ENPP1, TNAP, and ANK activities, the patent creates a self-regulating system that maintains pyrophosphate-phosphate balance and prevents pathological calcification when levels deviate from the physiological range
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ENPP1 agent effectively increases pyrophosphate levels, reducing calcification and bone overgrowth, ameliorating symptoms of DISH, Ankylosing Spondylitis, and Spondylarthritis, and restoring physiological ENPP1 activity.
Implementation Method 1
ENPP1 is a type-2 transmembrane protein whose extracellular activity hydrolyzes phosphodiester bonds of extracellular nucleotides, such as adenosine triphosphate (ATP), to generate adenosine monophosphate (AMP) and inorganic pyrophosphate (PPi)
Implementation Method 2
Because PPi is the main physiologic inhibitor of hydroxyapatite deposition, biallelic ENPP1 deficiency leads to ectopic mineralization in early life
Data Source
AI summary
The present disclosure provides, in one aspect, specific doses of an ENPP1 agent for in vivo treatment of Diffuse idiopathic skeletal hyperostosis (DISH), Ankylosing Spondylitis, and/or Spondylarthritis.